Last updated: August 2, 2026
Polyethylene glycol 3350, or PEG 3350, is a high-volume, low-differentiation pharmaceutical excipient with demand anchored by osmotic laxatives, oral powders, liquid formulations, tablets, capsules, and selected biopharmaceutical applications. Its commercial profile is driven more by manufacturing scale, pharmacopeial compliance, supply reliability, and formulation performance than by patent exclusivity.
The excipient itself has limited standalone pricing power. Value is concentrated in finished products such as MiraLAX, generic PEG 3350 laxatives, prescription bowel-preparation products, and proprietary formulations that use PEG as a carrier or stabilizer. Public companies generally do not report PEG 3350 revenue separately, so the market’s financial trajectory must be assessed through end-product demand, supplier capacity, raw-material economics, and regulatory requirements.
What is polyethylene glycol 3350 used for in pharmaceuticals?
PEG 3350 is a synthetic, water-soluble polyether used as an active pharmaceutical ingredient and excipient. Its principal characteristics are low toxicity, water miscibility, chemical stability, and limited systemic absorption when administered orally as an osmotic laxative.
Primary pharmaceutical applications
| Application |
Function of PEG 3350 |
Commercial relevance |
| Osmotic laxatives |
Draws water into the intestinal lumen |
Largest visible demand category |
| Oral powders |
Bulking, carrier, and dispersing medium |
Used in sachets and multidose bottles |
| Tablets and capsules |
Binder, lubricant, plasticizer, or coating component |
Secondary demand |
| Liquid and semisolid products |
Solubilizer and viscosity modifier |
Formulation-dependent |
| Biopharmaceutical formulations |
Stabilizer or excipient in selected systems |
Higher specification requirements |
| Drug delivery systems |
Hydrophilic polymer and surface-modifying component |
Technical and specialty segment |
PEG 3350 is commonly supplied as a white or nearly white, free-flowing powder. The number identifies the approximate average molecular weight, not a single molecular species. Molecular-weight distribution, moisture, residual ethylene oxide, dioxane, endotoxins, microbial quality, and heavy metals affect pharmaceutical suitability.
How large is the PEG 3350 pharmaceutical excipient market?
No authoritative public source reports a standalone global revenue figure for pharmaceutical-grade PEG 3350. Supplier disclosures typically combine PEG grades, molecular weights, pharmaceutical and industrial applications, or broader excipient categories.
A defensible market assessment therefore separates three layers:
- Pharmaceutical-grade PEG 3350 sold as an excipient or active ingredient.
- Finished PEG 3350 laxative and bowel-preparation products.
- Broader PEG sales across molecular weights, including industrial, cosmetic, and laboratory uses.
The first category is likely a relatively small share of the total polyethylene glycol market but has higher quality requirements and better margins than industrial grades. The second category captures most of the commercially visible value. The third category provides the manufacturing base and influences raw-material economics but is not a direct measure of pharmaceutical demand.
What is driving demand for PEG 3350?
Growth in constipation treatment
PEG 3350 benefits from persistent demand for treatment of occasional constipation, chronic constipation, opioid-induced constipation, and bowel irregularity. Its lack of stimulant-laxative pharmacology and generally favorable tolerability support recurring use in over-the-counter and prescription products.
The U.S. FDA permits PEG 3350 in certain laxative products under the OTC monograph framework, subject to applicable conditions and labeling requirements. MiraLAX was also approved as an NDA product for occasional constipation. The commercial market includes branded, store-brand, and generic products. [1,2]
Genericization and private-label expansion
The largest financial effect of PEG 3350’s mature product cycle is substitution from branded products to generic and private-label products. This raises total unit demand while reducing the price of finished products and weakening manufacturers’ ability to pass through excipient cost increases.
Retail pharmacy chains, mass merchants, warehouse clubs, and online sellers have expanded private-label laxative offerings. These products generally use the same active ingredient and depend on regulatory compliance, manufacturing reliability, packaging economics, and distribution rather than composition-of-matter differentiation.
Pediatric and chronic-use demand
Pediatric formulations and chronic constipation treatment create recurring demand, although dosing, flavoring, solubility, and labeling requirements add formulation complexity. Products designed for repeated administration can support stable volume even when consumer price competition remains intense.
Bowel-preparation products
PEG-based bowel preparations can generate greater volume per patient than standard constipation products. Demand is tied to colonoscopy utilization, gastroenterology procedures, hospital activity, and demographic trends. Bowel-preparation products may use PEG 3350 or higher-molecular-weight PEG systems with electrolytes and other active components, so procedure growth does not translate one-for-one into PEG 3350 excipient demand.
What factors determine PEG 3350 pricing?
PEG 3350 is generally a cost-sensitive excipient. Pricing is affected by:
- Ethylene oxide and other petrochemical feedstock costs.
- Polymerization energy requirements.
- Pharmaceutical-grade purification and testing.
- Batch size and manufacturing utilization.
- Geographic freight and packaging costs.
- Qualification status with pharmaceutical customers.
- Supply contracts and dual-sourcing requirements.
- Pharmacopeial and customer-specific specifications.
- Regulatory documentation, including GMP records and change-control obligations.
The excipient’s molecular identity is not difficult to replicate. Supplier switching is therefore technically possible, but pharmaceutical customers may require method transfer, comparative testing, stability work, quality agreements, and regulatory notification before changing sources. These switching costs support incumbent suppliers without creating strong patent-based barriers.
Which companies supply pharmaceutical-grade PEG 3350?
The global supply base includes large chemical manufacturers, specialty excipient suppliers, pharmaceutical distributors, and contract manufacturers. Commercial product families include PEG and Polyglykol grades from major chemical companies such as BASF and Clariant, along with regional and specialist suppliers.
| Supplier group |
Competitive advantage |
Principal limitation |
| Large chemical producers |
Scale, integrated feedstocks, global quality systems |
Less flexibility for small customers |
| Specialty excipient suppliers |
Documentation, formulation support, smaller batch service |
Higher unit cost |
| Regional manufacturers |
Local supply and shorter logistics routes |
Variable global regulatory coverage |
| Distributors |
Inventory and customer access |
Limited control over manufacturing capacity |
| Contract manufacturers |
Custom packaging and qualification support |
Dependence on upstream polymer supply |
Supplier qualification is often more important than nominal list price. Pharmaceutical customers evaluate certificates of analysis, GMP systems, audit history, change-control performance, elemental impurities, residual solvents, microbiological controls, and continuity plans.
How strong is the patent estate for PEG 3350?
The patent position around PEG 3350 itself is weak because PEG is an established polymer with long commercial use and no practical composition-of-matter exclusivity for the basic excipient.
What patents protect PEG 3350 products?
Protection may exist at the finished-product level for:
- Specific PEG 3350 formulations.
- Electrolyte combinations.
- Flavoring and dosing systems.
- Drug combinations.
- Pediatric dosing methods.
- Bowel-preparation regimens.
- Packaging and delivery systems.
- Manufacturing or purification processes.
Those rights do not generally create broad exclusivity over pharmaceutical-grade PEG 3350 as a raw material. Product-specific patents must be assessed separately from the excipient’s regulatory status.
What is the Orange Book status of PEG 3350?
The FDA Orange Book concerns approved drug products, patents, and exclusivity associated with approved applications. It does not create a standalone patent listing for PEG 3350 as an excipient. A PEG 3350 product may have an NDA, ANDA, or OTC-monograph status, but that status does not establish exclusivity over the polymer itself. [3]
When does PEG 3350 lose exclusivity?
PEG 3350 has no meaningful molecule-level exclusivity period comparable to a new chemical entity. The relevant exclusivity dates are those of particular finished products.
| Exclusivity layer |
Commercial effect |
| Basic PEG 3350 material |
No meaningful composition exclusivity |
| NDA product |
May receive product-specific regulatory exclusivity |
| OTC-monograph product |
Generally competes under monograph conditions |
| Formulation patent |
Can restrict copying of the claimed formulation |
| Method-of-use patent |
Can restrict a defined therapeutic use |
| Manufacturing patent |
May protect a specific process, not the polymer broadly |
| Trademark |
Protects brand identity, not ingredient supply |
MiraLAX’s commercial position is therefore based primarily on brand recognition, distribution, labeling, consumer trust, and retail placement rather than continuing exclusivity over PEG 3350. Kenvue identifies MiraLAX among its consumer health brands, but does not separately report brand revenue in its public financial statements. [4]
Which companies are challenging PEG 3350 products?
The principal competitive challenge comes from generic manufacturers, private-label suppliers, and retail brands rather than from patent challengers targeting PEG 3350 itself.
Potential competitors include:
- Generic drug manufacturers with approved PEG 3350 products.
- Contract manufacturers supplying store brands.
- Branded laxative companies.
- Bowel-preparation manufacturers.
- Retail pharmacy and e-commerce private labels.
Paragraph IV litigation is product-specific. A generic applicant may file a Paragraph IV certification against listed patents for an approved PEG 3350 drug product, but a challenge to a product patent would not invalidate the broader use of PEG 3350 as an excipient. [3]
What FDA regulatory requirements apply to PEG 3350?
Regulatory requirements depend on whether PEG 3350 is used as an active ingredient or excipient.
Active pharmaceutical ingredient
For laxative products, PEG 3350 is subject to applicable FDA drug requirements, including identity, strength, quality, manufacturing controls, labeling, and product testing. OTC products must comply with the applicable monograph framework or obtain approval through an NDA or other permitted pathway. [1,2]
Pharmaceutical excipient
As an excipient, PEG 3350 must meet the specifications established in the applicable pharmacopeial monograph, commonly USP-NF where required by the customer or market. Manufacturers must also demonstrate consistent control of impurities and maintain appropriate GMP systems.
Important quality attributes include:
- Average molecular weight and molecular-weight distribution.
- Water content.
- Ethylene oxide and dioxane residues.
- Acidity or alkalinity.
- Heavy metals and elemental impurities.
- Microbial limits.
- Endotoxin controls for applicable products.
- Appearance, solubility, and flow characteristics.
The FDA Inactive Ingredient Database is a useful reference for historical excipient use in approved drug products, but database presence does not automatically establish suitability for every route, dosage form, concentration, or patient population. [5]
What manufacturing and intellectual-property barriers exist?
PEG 3350 manufacturing is capital-intensive but not strongly protected by intellectual property. The main barriers are operational.
Manufacturing barriers
Production requires controlled ethoxylation or polymerization processes, specialized equipment, quality testing, and safe handling of ethylene oxide. Pharmaceutical-grade production also requires segregation or validated cleaning, traceability, robust analytical methods, and documented change control.
The most material risks are:
- Feedstock interruption.
- Ethylene oxide plant outages.
- Contamination or cross-contamination.
- Batch failures.
- Regulatory observations.
- Long customer requalification cycles.
- Limited capacity for highly specific grades.
- Transportation restrictions and regional inventory gaps.
Intellectual-property barriers
IP barriers are stronger for derivative products than for the base polymer. Proprietary bowel-preparation compositions, delivery systems, conjugates, and specialty formulations may carry enforceable rights. The underlying PEG 3350 material generally does not provide a durable exclusionary position.
How does PEG 3350 compare with other pharmaceutical excipients?
| Excipient |
Main use |
Differentiation |
Pricing power |
| PEG 3350 |
Osmotic laxative, carrier, stabilizer |
Low to moderate |
Low |
| PEG 400 |
Solvent and plasticizer |
Low |
Low |
| Povidone |
Binder and solubilizer |
Moderate |
Moderate |
| Crospovidone |
Disintegrant |
Moderate |
Moderate |
| Hypromellose |
Coating and controlled release |
Moderate to high |
Moderate |
| Poloxamer 188 |
Solubilizer and biologic stabilizer |
Higher specification sensitivity |
Moderate to high |
| Lactose |
Filler and carrier |
Low |
Low |
| Mannitol |
Diluent and lyoprotectant |
Moderate |
Moderate |
PEG 3350 is more exposed to commodity economics than specialty excipients used in complex biologics or controlled-release systems. Its advantage is broad functionality and established regulatory history. Its disadvantage is limited differentiation.
What is the financial trajectory for PEG 3350?
The most probable financial trajectory is steady pharmaceutical volume growth with limited unit-price growth.
Revenue drivers
Finished-product revenue should be supported by:
- Aging populations.
- Chronic constipation treatment.
- Continued colonoscopy activity.
- Generic and private-label product expansion.
- Increased use of convenient powder formats.
- Demand for well-characterized excipients in oral and biopharmaceutical products.
Margin pressures
Supplier margins face pressure from:
- Commodity-style competition.
- Customer concentration.
- Generic drug pricing.
- Retailer purchasing power.
- Feedstock volatility.
- Qualification-based bidding.
- Limited ability to differentiate standard PEG 3350 grades.
Specialty pharmaceutical grades, small-pack supply, validated sterile applications, and customer-specific documentation can produce better margins than bulk standard material. The highest-value opportunities are likely to come from formulation services, regulatory support, supply assurance, and specialty PEG systems rather than from unmodified PEG 3350 volume alone.
Revenue exposure by business model
| Business model |
PEG 3350 exposure |
Financial profile |
| Bulk chemical producer |
Direct but often aggregated |
High volume, lower margin |
| Excipient supplier |
Direct |
Moderate margin, qualification-driven |
| Generic laxative company |
Product-level |
Low unit price, scale-dependent |
| Branded consumer-health company |
Brand-level |
Higher marketing value, ingredient cost is small |
| Specialty drug-delivery company |
Formulation-level |
Lower volume, potentially higher margin |
| Distributor |
Inventory-based |
Working-capital and logistics exposure |
What generic launch risks exist for PEG 3350 products?
Generic launch risk is high for standard PEG 3350 laxative products because the active ingredient is established, the dosage form is relatively simple, and consumers can switch based on price.
The principal barriers are regulatory and commercial:
- Bioequivalence or product-performance requirements.
- Labeling compliance.
- Manufacturing scale.
- Retail distribution.
- Packaging and flavor acceptability.
- Supply continuity.
- Brand and private-label contracting.
- Any remaining product-specific patents or exclusivities.
For suppliers of PEG 3350, generic launches can increase raw-material demand while reducing finished-product prices. For branded manufacturers, generic entry creates direct revenue and market-share pressure.
What licensing deals and litigation affect PEG 3350?
There is no widely reported licensing market for the basic PEG 3350 excipient comparable to licensing for patented active pharmaceutical ingredients. Licensing may arise in specific formulations, branded products, manufacturing processes, or drug-delivery platforms.
Litigation risk is also concentrated at the finished-product level. Relevant disputes may involve:
- Product patents.
- ANDA Paragraph IV filings.
- Labeling and method-of-use claims.
- Manufacturing contracts.
- Product liability.
- Quality failures.
- Supply agreements.
No broad patent litigation is required to commercialize standard pharmaceutical-grade PEG 3350. The commercial risk is more likely to involve supply, regulatory compliance, and price competition.
What is the competitive outlook for PEG 3350?
The market has a stable base but limited structural pricing power. Large suppliers with global GMP coverage, reliable ethylene oxide access, and strong regulatory documentation should retain an advantage. Smaller suppliers can compete through regional inventory, customer service, custom packaging, and flexible batch sizes.
The strongest commercial positions are likely to be held by companies that combine:
- Multiple manufacturing sites or qualified sources.
- Pharmaceutical-grade documentation.
- Short lead times.
- Low impurity variability.
- Customer-specific regulatory support.
- Ability to supply both standard and specialty molecular-weight grades.
Key Takeaways
- PEG 3350 is a mature, high-volume pharmaceutical polymer with low molecule-level patent protection.
- The largest commercial application is osmotic laxative products, including branded, generic, and private-label products.
- Public companies do not generally disclose standalone PEG 3350 excipient revenue.
- Finished-product revenue is more commercially important than raw-material revenue.
- Demand should remain stable to moderately growing, while unit pricing faces commodity and generic-drug pressure.
- Manufacturing quality, supply continuity, and regulatory documentation are more important barriers than intellectual property.
- Formulation, bowel-preparation, delivery-system, and method-of-use patents may protect specific products but not PEG 3350 broadly.
- Generic competition is a major risk for branded PEG 3350 products and a potential volume driver for excipient suppliers.
- PEG 3350 is less differentiated and less profitable than specialty excipients used in complex biologic and controlled-release formulations.
FAQs
Is PEG 3350 an API or an excipient?
It can be either. In laxative products, PEG 3350 is the active ingredient. In other pharmaceutical formulations, it can function as a solvent, carrier, plasticizer, stabilizer, binder, or delivery-system component.
Is pharmaceutical-grade PEG 3350 different from industrial PEG?
Yes. Pharmaceutical-grade material is produced and tested under more stringent quality controls. Impurity limits, documentation, GMP compliance, traceability, and change-control requirements distinguish it from industrial grades.
Can a company patent PEG 3350?
A company generally cannot obtain broad, durable composition protection for the established PEG 3350 polymer. It may patent a particular formulation, manufacturing process, combination, dosage regimen, or delivery system.
Does PEG 3350 have biosimilar competition?
No. PEG 3350 is a synthetic polymer, not a biologic. Biosimilar pathways do not apply to the excipient itself. Competition comes from generic drugs, private-label products, and alternative laxative formulations.
What is the largest commercial risk for PEG 3350 suppliers?
The largest risks are feedstock disruption, manufacturing outages, quality failures, customer requalification delays, and price competition. Patent expiration is not the primary risk for the basic excipient.
References
-
U.S. Food and Drug Administration. (2022). Laxative drug products for over-the-counter human use. Code of Federal Regulations, 21 C.F.R. Part 331.
-
U.S. Food and Drug Administration. (2006). MiraLAX polyethylene glycol 3350, NDA 021587. Drugs@FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.
-
Kenvue Inc. (2024). Annual report for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission.
-
U.S. Food and Drug Administration. (2024). Inactive ingredient database. FDA Center for Drug Evaluation and Research.
-
United States Pharmacopeia. (2024). Polyethylene glycol monograph. United States Pharmacopeia-National Formulary.
